Head to Head Analysis: Cannlabs (OTCMKTS:CANL) & NeuroOne Medical Technologies (NASDAQ:NMTC)

NeuroOne Medical Technologies (NASDAQ:NMTC) and Cannlabs (OTCMKTS:CANL) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation.

Volatility & Risk

NeuroOne Medical Technologies has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500. Comparatively, Cannlabs has a beta of 1.75, indicating that its stock price is 75% more volatile than the S&P 500.

Insider & Institutional Ownership

16.1% of NeuroOne Medical Technologies shares are held by institutional investors. 8.9% of NeuroOne Medical Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares NeuroOne Medical Technologies and Cannlabs”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroOne Medical Technologies	$12.10 million	3.59	-$3.61 million	($0.08)	-10.78
Cannlabs	N/A	N/A	N/A	N/A	N/A

Cannlabs has lower revenue, but higher earnings than NeuroOne Medical Technologies.

Analyst Ratings

This is a breakdown of recent ratings and target prices for NeuroOne Medical Technologies and Cannlabs, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroOne Medical Technologies	1	0	2	1	2.75
Cannlabs	0	0	0	0	0.00

NeuroOne Medical Technologies presently has a consensus price target of $2.23, suggesting a potential upside of 158.12%. Given NeuroOne Medical Technologies’ stronger consensus rating and higher probable upside, equities research analysts plainly believe NeuroOne Medical Technologies is more favorable than Cannlabs.

Profitability

This table compares NeuroOne Medical Technologies and Cannlabs’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NeuroOne Medical Technologies	-29.81%	-74.69%	-44.31%
Cannlabs	N/A	N/A	N/A

Summary

NeuroOne Medical Technologies beats Cannlabs on 7 of the 11 factors compared between the two stocks.

About NeuroOne Medical Technologies

NeuroOne Medical Technologies Corporation, a developmental stage company, provides solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other related neurological disorders. It also fucuses on applications for other areas, such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator. The company was incorporated in 2009 and is based in Eden Prairie, Minnesota.

About Cannlabs

CannLabs, Inc. provides cannabis testing laboratory services in the United States. Its testing services include potency testing, residual solvent analysis, microbiological testing, pesticide testing, heavy metals testing, nutrient analysis, terpenes analysis, shelf-life/stability studies, gene expression testing, and genotyping/phenotyping testing. The company also offers data/analytics and consulting, as well as education services. CannLabs, Inc. was incorporated in 2010 and is based in Denver, Colorado.